Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
SpringWorks Therapeutics, Inc. (SWTX)
|
Add to portfolio |
|
|
|
| Price: |
$65.46
| | Metrics |
| OS: |
62.5
|
M
| |
-41
|
% ROE
|
| Market cap: |
$4.09
|
B
| |
-44
|
% ROIC
|
|
Net cash:
|
$597
|
M
| |
$9.55
|
per share
|
|
EV:
|
$3.49
|
B
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
($228)
|
M
| |
|
|
|
EBIT
|
($228)
|
M
| |
|
|
| EPS |
($4.67)
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-22 | Dec-31-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 |
| Revenues | 0.0 | 0.0 | 35.0 | 3.5 | 0.7 |
| Revenue growth | | -100.0% | 886.7% | 423.2% | |
| Cost of goods sold | 0.0 | 0.0 | 0.0 | 3.5 | 0.7 |
| Gross profit | 0.0 | 0.0 | 35.0 | 0.0 | 0.0 |
| Gross margin | | | 100.0% | 0.0% | 0.0% |
| Research and development | 146.1 | 101.7 | 51.9 | 42.5 | 9.9 |
| General and administrative | 134.6 | 71.8 | 29.5 | 16.7 | 8.6 |
| EBIT | -283.6 | -174.5 | -46.9 | -61.9 | -18.5 |
| EBIT margin | | | -134.1% | -1743.8% | -2727.3% |
| Pre-tax income | -277.4 | -173.9 | -45.6 | -58.3 | -17.8 |
| Income taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Tax rate | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | -277.4 | -173.9 | -45.6 | -50.6 | -17.8 |
| Net margin | | | -130.2% | -1425.9% | -2627.3% |
| |
| Diluted EPS | ($5.21) | ($3.59) | ($1.05) | ($3.81) | |
| Shares outstanding (diluted) | 53.3 | 48.5 | 43.3 | 13.3 | |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|